Indication intelligence, analysis and sector perception

ImmunoCellular Therapeutics (NYSEMKT: IMUC) $19.9 M grant from the California Institute for Regenerative Medicine (CIRM). Trading UP +$0.10 to $0.57 or +22.56% - BUY

September 24, 2015 3:07pm

IMUC closed at $0.47 and share trading had been halted but is “cooking-up” past the 3 pm hour. BUY

IMUC was awarded $19.9 M grant by the California Institute for Regenerative Medicine to fund ICT-107 P3 registration program in Glioblastoma.

ImmunoCellular says it is on track to initiate the phase 3 ICT-107 trial in Q4/15, which will include approximately 120 clinical sites in the US, Europe and Canada, and will recruit about 400 patients.

The Bottom Line: From no where’s Ville to back on the map! It’s still all about non-dilutive capital assisting its current cash to facilitate trials. IMUC has also reached agreement with the US FDA on a Special Protocol Assessment relative to the primary and secondary endpoints as well as the statistical plan for the P3 trial. The $19.9 million CIRM grant funds will be received over the duration of the trial as specified milestones are achieved.

ImmunoCellular Therapeutics (NYSEMKT: IMUC) is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. IMUC had concluded a P2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. IMUC's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.